Dihydropyrazine activates the CAMKK2-AMPK-ULK1 signaling pathway in human hepatoma HepG2 cells
The Journal of Toxicological Sciences · 2025
DOI: 10.2131/jts.50.577 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Toxicological Sciences, 2025. Verfasst von Madoka Sawai und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy at Fukuoka, International University of Health and Welfare. Hauptthemen laut MEDLINE: Autophagy-Related Protein-1 Homolog, Calcium-Calmodulin-Dependent Protein Kinase Kinase, AMP-Activated Protein Kinases, Signal Transduction. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy at Fukuoka, International University of Health and Welfare.
- Faculty of Pharmaceutical Sciences, Sojo University.
Zitieren
APA
Sawai, M., Miyauchi, Y., Kansui, H., & Takechi, S. (2025). Dihydropyrazine activates the CAMKK2-AMPK-ULK1 signaling pathway in human hepatoma HepG2 cells. The Journal of Toxicological Sciences. https://doi.org/10.2131/jts.50.577
Vancouver
Sawai M, Miyauchi Y, Kansui H, Takechi S. Dihydropyrazine activates the CAMKK2-AMPK-ULK1 signaling pathway in human hepatoma HepG2 cells. The Journal of Toxicological Sciences. 2025. doi:10.2131/jts.50.577
BibTeX
@article{Sawai2025,
author = {Sawai, Madoka and Miyauchi, Yuu and Kansui, Hisao and Takechi, Shinji},
title = {Dihydropyrazine activates the CAMKK2-AMPK-ULK1 signaling pathway in human hepatoma HepG2 cells},
journal = {The Journal of Toxicological Sciences},
year = {2025},
doi = {10.2131/jts.50.577}
}
EUVIMED